Description |
dipeptidyl peptidase 4 |
C-X-C motif chemokine ligand 12 |
Image |
|
|
GO Annotations |
Cellular Component |
|
|
Molecular Function |
|
|
Biological Process |
|
|
Pathways |
|
|
Drugs |
- Atorvastatin
- Sitagliptin
- 2-Amino-3-Methyl-1-Pyrrolidin-1-Yl-Butan-1-One
- 5-(Aminomethyl)-6-(2,4-Dichlorophenyl)-2-(3,5-Dimethoxyphenyl)Pyrimidin-4-Amine
- (2s)-Pyrrolidin-2-Ylmethylamine
- 4-Iodo-L-phenylalanine
- Diisopropylphosphono Group
- 1-(1-phenylcyclopentyl)methylamine
- (S)-2-[(R)-3-amino-4-(2-fluorophenyl)butyryl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide
- Vildagliptin
- PSN9301
- KRP-104
- Alogliptin
- Saxagliptin
- (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-PROP-1-YN-1-YLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
- N-(TRANS-4-{(1S,2S)-2-AMINO-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-1-METHYL-3-OXOPROPYL}CYCLOHEXYL)-N-METHYLACETAMIDE
- (2S,3S)-4-cyclopropyl-3-{(3R,5R)-3-[2-fluoro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazolidin-5-yl}-1-[(3S)-3-fluoropyrrolidin-1-yl]-1-oxobutan-2-amine
- (2S,3S)-3-{3-[2-chloro-4-(methylsulfonyl)phenyl]-1,2,4-oxadiazol-5-yl}-1-cyclopentylidene-4-cyclopropyl-1-fluorobutan-2-amine
- (3R,4R)-4-(pyrrolidin-1-ylcarbonyl)-1-(quinoxalin-2-ylcarbonyl)pyrrolidin-3-amine
- (7R,8R)-8-(2,4,5-trifluorophenyl)-6,7,8,9-tetrahydroimidazo[1,2-a:4,5-c']dipyridin-7-amine
- (2S,3S)-3-{3-[4-(METHYLSULFONYL)PHENYL]-1,2,4-OXADIAZOL-5-YL}-1-OXO-1-PYRROLIDIN-1-YLBUTAN-2-AMINE
- (1S,2R,5S)-5-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-2-(2,4,5-TRIFLUOROPHENYL)CYCLOHEXANAMINE
- (2R)-4-[(8R)-8-METHYL-2-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[1,5-A]PYRAZIN-7(8H)-YL]-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
- (2S,3S)-3-AMINO-4-(3,3-DIFLUOROPYRROLIDIN-1-YL)-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-6-YLCYCLOHEXYL)BUTANAMIDE
- (2S,3S)-3-AMINO-4-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-N,N-DIMETHYL-4-OXO-2-(TRANS-4-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-5-YLCYCLOHEXYL)BUTANAMIDE
- (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-METHYL-1,4-DIAZEPAN-2-ONE
- 4'-[(1R)-1-amino-2-(2,5-difluorophenyl)ethyl]biphenyl-3-carboxamide
- (2R,3R)-7-(methylsulfonyl)-3-(2,4,5-trifluorophenyl)-1,2,3,4-tetrahydropyrido[1,2-a]benzimidazol-2-amine
- 7-(aminomethyl)-6-(2-chlorophenyl)-1-methyl-1H-benzimidazole-5-carbonitrile
- (3R)-4-[(3R)-3-AMINO-4-(2,4,5-TRIFLUOROPHENYL)BUTANOYL]-3-(2,2,2-TRIFLUOROETHYL)-1,4-DIAZEPAN-2-ONE
- METHYL 4-{[({[(2R,5S)-5-{[(2S)-2-(AMINOMETHYL)PYRROLIDIN-1-YL]CARBONYL}PYRROLIDIN-2-YL]METHYL}AMINO)CARBONYL]AMINO}BENZOATE
- (1S)-2-[(2S,5R)-2-(AMINOMETHYL)-5-ETHYNYLPYRROLIDIN-1-YL]-1-CYCLOPENTYL-2-OXOETHANAMINE
- 1-biphenyl-2-ylmethanamine
- (1S,3S,5S)-2-{(2S)-2-amino-2-[(1R,3S,5R,7S)-3-hydroxytricyclo[3.3.1.1~3,7~]dec-1-yl]acetyl}-2-azabicyclo[3.1.0]hexane-3-carbonitrile
- (2R)-N-[(2R)-2-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-N-[(5R)-5-(DIHYDROXYBORYL)-1-L-PROLYLPYRROLIDIN-2-YL]-L-PROLINAMIDE
- (3R,4S)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
- N-({(2S)-1-[(3R)-3-AMINO-4-(2-FLUOROPHENYL)BUTANOYL]PYRROLIDIN-2-YL}METHYL)BENZAMIDE
- (4R,5R)-5-AMINO-1-[2-(1,3-BENZODIOXOL-5-YL)ETHYL]-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-2-ONE
- (3R,4S)-1-(3,4-DIMETHOXYPHENYL)-3-(3-METHYLPHENYL)PIPERIDIN-4-AMINE
- 1-[2-(S)-AMINO-3-BIPHENYL-4-YL-PROPIONYL]-PYRROLIDINE-2-(S)-CARBONITRILE
- (1S,6R)-3-{[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]CARBONYL}-6-(2,4,5-TRIFLUOROPHENYL)CYCLOHEX-3-EN-1-AMINE
- (2R)-4-(2-BENZOYL-1,2-DIAZEPAN-1-YL)-4-OXO-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE
- (3R,4R)-1-{6-[3-(METHYLSULFONYL)PHENYL]PYRIMIDIN-4-YL}-4-(2,4,5-TRIFLUOROPHENYL)PIPERIDIN-3-AMINE
- Gosogliptin
- N-({(2S)-1-[(3R)-3-amino-4-(3-chlorophenyl)butanoyl]pyrrolidin-2-yl}methyl)-3-(methylsulfonyl)benzamide
- (3R,4S)-1-[6-(6-METHOXYPYRIDIN-3-YL)PYRIMIDIN-4-YL]-4-(2,4,5-TRIFLUOROPHENYL)PYRROLIDIN-3-AMINE
- 6-(4-{(1S,2S)-2-AMINO-1-[(DIMETHYLAMINO)CARBONYL]-3-[(3S)-3-FLUOROPYRROLIDIN-1-YL]-3-OXOPROPYL}PHENYL)-1H-[1,2,4]TRIAZOLO[1,5-A]PYRIDIN-4-IUM
- 7-BENZYL-1,3-DIMETHYL-8-PIPERAZIN-1-YL-3,7-DIHYDRO-PURINE-2,6-DIONE
- 2-({2-[(3R)-3-AMINOPIPERIDIN-1-YL]-4-OXOQUINAZOLIN-3(4H)-YL}METHYL)BENZONITRILE
- 4-[(3R)-3-{[2-(4-FLUOROPHENYL)-2-OXOETHYL]AMINO}BUTYL]BENZAMIDE
- 2-({8-[(3R)-3-AMINOPIPERIDIN-1-YL]-1,3-DIMETHYL-2,6-DIOXO-1,2,3,6-TETRAHYDRO-7H-PURIN-7-YL}METHYL)BENZONITRILE
- Linagliptin
- Dutogliptin
|
|
Diseases |
|
|
GWAS |
|
- Blood protein levels ( 30072576)
- Body mass index ( 25760438)
- Coronary artery disease ( 26708285 24262325 26343387)
- Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease) ( 28714975)
- Coronary heart disease ( 17634449 21378990)
- Diastolic blood pressure ( 27841878)
- Granulocyte count ( 27863252)
- Left superior temporal gyrus thickness (schizophrenia interaction) ( 26249676)
- Monocyte count ( 27863252)
- Myeloid white cell count ( 27863252)
- Myocardial infarction ( 26343387)
- Myocardial infarction (early onset) ( 19198609)
- Neutrophil count ( 27863252)
- QT interval (ambient particulate matter interaction) ( 28749367)
- Resistance to Mycobacterium tuberculosis in HIV-positive individuals measured by a negative tuberculin skin test (continuous) ( 28628665)
- Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy) ( 24554482)
- Schizophrenia ( 23212062)
- Smoking initiation (ever regular vs never regular) ( 31089300)
- Sum basophil neutrophil counts ( 27863252)
- Sum neutrophil eosinophil counts ( 27863252)
- White blood cell count ( 27863252)
|
Interacting Genes |
16 interacting genes:
ADA
CCL11
CCL22
CCL3L1
CCL5
CD4
CPAMD8
CXCL10
CXCL11
CXCL12
CXCL9
CXCR4
DKK1
FAP
GRP
PTPRC
|
11 interacting genes:
CD4
CTSG
CXCR4
DAZAP2
DPP4
ELANE
FBXO7
FN1
MMP2
PF4
VCAN
|
Entrez ID |
1803 |
6387 |
HPRD ID |
02187 |
02904 |
Ensembl ID |
ENSG00000197635
|
ENSG00000107562
|
Uniprot IDs |
P27487
|
P48061
|
PDB IDs |
1J2E
1N1M
1NU6
1NU8
1PFQ
1R9M
1R9N
1RWQ
1TK3
1TKR
1U8E
1W1I
1WCY
1X70
2AJL
2BGN
2BGR
2BUB
2FJP
2G5P
2G5T
2G63
2HHA
2I03
2I78
2IIT
2IIV
2JID
2OAG
2OGZ
2OLE
2ONC
2OPH
2OQI
2OQV
2P8S
2QJR
2QKY
2QOE
2QT9
2QTB
2RGU
2RIP
3BJM
3C43
3C45
3CCB
3CCC
3D4L
3EIO
3F8S
3G0B
3G0C
3G0D
3G0G
3H0C
3HAB
3HAC
3KWF
3KWJ
3NOX
3O95
3O9V
3OC0
3OPM
3Q0T
3Q8W
3QBJ
3SWW
3SX4
3VJK
3VJL
3VJM
3W2T
3WQH
4A5S
4DSA
4DSZ
4DTC
4G1F
4J3J
4JH0
4KR0
4L72
4LKO
4N8D
4N8E
4PNZ
4PV7
4QZV
5I7U
5ISM
5J3J
5KBY
5T4B
5T4E
5T4F
5T4H
5Y7H
5Y7J
5Y7K
5ZID
6B1E
6B1O
|
1A15
1QG7
1SDF
1VMC
2J7Z
2K01
2K03
2K04
2K05
2KEC
2KED
2KEE
2KOL
2N55
2NWG
2SDF
3GV3
3HP3
4LMQ
4UAI
|
Enriched GO Terms of Interacting Partners? |
|
|
Tagcloud ? |
|
|
Tagcloud (Difference) ? |
|
|
Tagcloud (Intersection) ? |
|